This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pili, R. Articles by Carducci, M. A. Search for Related Content PubMed PubMed Citation Articles by Pili, R. Articles by Carducci, M. A.

Combination of Phenylbutyrate and 13-cis Retinoic Acid Inhibits Prostate Tumor Growth and Angiogenesis¹

The Johns Hopkins Oncology Center, Baltimore, Maryland 21231

Differentiation-inducing agents, such as retinoids and short-chain fatty acids, have an inhibitory effect on tumor cell proliferation and tumor growth in preclinical studies. Clinical trials involving these compounds as single agents have been suboptimal in terms of clinical benefit. Our study evaluated the combination of phenylbutyrate (PB) and 13-cis retinoic acid (CRA) as a differentiation and antiangiogenesis strategy for prostate cancer. On the basis of previous evidence, common signal transduction pathways and possible modulation of retinoid receptors and retinoid response elements by PB could be responsible for such activities. We assessed the effect of the combination of PB and CRA on human and rodent prostate carcinoma cell lines. The combination of PB and CRA inhibited cell proliferation and increased apoptosis in vitro in an additive fashion as compared with single agents (P < 0.014). Prostate tumor cells treated with both PB and CRA revealed an increased expression of a subtype of retinoic acid receptor (retinoic acid receptor-ß), suggesting a molecular mechanism for the biological additive effect. The combination of PB and CRA also inhibited prostate tumor growth in vivo (up to 82–92%) as compared with single agents (P < 0.025). Histological examination of tumor xenografts revealed decreased in vivo tumor cell proliferation, an increased apoptosis rate, and a reduced microvessel density in the animals treated with combined drugs, suggesting an antiangiogenesis effect of this combination. Thus, endothelial cell treatment with both PB and CRA resulted in reduced in vitro cell proliferation. In vivo testing using the Matrigel angiogenesis assay showed an additive inhibitory effect in the animals treated with a combination of PB + CRA (P < 0.004 versus single agents). In summary, this study showed an additive inhibitory effect of combination of differentiation agents PB and CRA on prostate tumor growth through a direct effect on both tumor and endothelial cells.

This article has been cited by other articles:

				Y. Kato, B. C. Salumbides, X.-F. Wang, D. Z. Qian, S. Williams, Y. Wei, T. B. Sanni, P. Atadja, and R. Pili Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma Mol. Cancer Ther., January 1, 2007; 6(1): 70 - 81. [Abstract] [Full Text] [PDF]

				D. Z. Qian, Y. Kato, S. Shabbeer, Y. Wei, H. M.W. Verheul, B. Salumbides, T. Sanni, P. Atadja, and R. Pili Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 Clin. Cancer Res., January 15, 2006; 12(2): 634 - 642. [Abstract] [Full Text] [PDF]

				X.-f. Wang, D. Z. Qian, M. Ren, Y. Kato, Y. Wei, L. Zhang, Z. Fansler, D. Clark, O. Nakanishi, and R. Pili Epigenetic Modulation of Retinoic Acid Receptor {beta}2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma Clin. Cancer Res., May 1, 2005; 11(9): 3535 - 3542. [Abstract] [Full Text] [PDF]

				S. E. Touma, J. S. Goldberg, P. Moench, X. Guo, S. K. Tickoo, L. J. Gudas, and D. M. Nanus Retinoic Acid and the Histone Deacetylase Inhibitor Trichostatin A Inhibit the Proliferation of Human Renal Cell Carcinoma in a Xenograft Tumor Model Clin. Cancer Res., May 1, 2005; 11(9): 3558 - 3566. [Abstract] [Full Text] [PDF]

				K. N. Prasad Multiple Dietary Antioxidants Enhance the Efficacy of Standard and Experimental Cancer Therapies and Decrease Their Toxicity Integr Cancer Ther, December 1, 2004; 3(4): 310 - 322. [Abstract] [PDF]

				D. Z. Qian, X. Wang, S. K. Kachhap, Y. Kato, Y. Wei, L. Zhang, P. Atadja, and R. Pili The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Cancer Res., September 15, 2004; 64(18): 6626 - 6634. [Abstract] [Full Text] [PDF]

				R. Lotan and Y. Lotan Retinoic Acid Receptor {beta}2 Hypermethylation: Implications for Prostate Cancer Detection, Prevention, and Therapy Clin. Cancer Res., June 15, 2004; 10(12): 3935 - 3936. [Full Text] [PDF]

				M. Michaelis, U. R. Michaelis, I. Fleming, T. Suhan, J. Cinatl, R. A. Blaheta, K. Hoffmann, R. Kotchetkov, R. Busse, H. Nau, et al. Valproic Acid Inhibits Angiogenesis in Vitro and in Vivo Mol. Pharmacol., March 1, 2004; 65(3): 520 - 527. [Abstract] [Full Text] [PDF]

				M. Simeoni, P. Magni, C. Cammia, G. De Nicolao, V. Croci, E. Pesenti, M. Germani, I. Poggesi, and M. Rocchetti Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents Cancer Res., February 1, 2004; 64(3): 1094 - 1101. [Abstract] [Full Text] [PDF]

				C. Pellizzaro, D. Coradini, and M. G. Daidone Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29 Carcinogenesis, May 1, 2002; 23(5): 735 - 740. [Abstract] [Full Text] [PDF]

				V. Vivat-Hannah, D. You, C. Rizzo, J.-P. Daris, P. Lapointe, F. C. Zusi, A. Marinier, M. V. Lorenzi, and M. M. Gottardis Synergistic Cytotoxicity Exhibited by Combination Treatment of Selective Retinoid Ligands with Taxol (Paclitaxel) Cancer Res., December 1, 2001; 61(24): 8703 - 8711. [Abstract] [Full Text] [PDF]

				M. A. Carducci, J. Gilbert, M. K. Bowling, D. Noe, M. A. Eisenberger, V. Sinibaldi, Y. Zabelina, T.-l. Chen, L. B. Grochow, and R. C. Donehower A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule Clin. Cancer Res., October 1, 2001; 7(10): 3047 - 3055. [Abstract] [Full Text] [PDF]